Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?

[1]  A. Toss,et al.  Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? , 2020, Expert opinion on drug safety.

[2]  T. Ind,et al.  Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO) , 2019, Journal of Ovarian Research.

[3]  A. Toss,et al.  Hereditary ovarian cancers: state of the art. , 2019, Minerva medica.

[4]  W. Dinjens,et al.  Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. , 2019, Gynecologic oncology.

[5]  E. Friedman,et al.  Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers , 2018, Cancer.

[6]  A. Vecchiola,et al.  Gynecological–endocrinological aspects in women carriers of BRCA1/2 gene mutations , 2018, Climacteric : the journal of the International Menopause Society.

[7]  Yujian Shi,et al.  BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. , 2018, Gynecologic oncology.

[8]  I. Shih,et al.  Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study , 2018, Cancer Prevention Research.

[9]  G. D. de Bock,et al.  Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy. , 2018, Maturitas.

[10]  L. Minig,et al.  Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study , 2018, Clinical and Translational Oncology.

[11]  C. Marchetti,et al.  Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know. , 2017, Cancer treatment reviews.

[12]  M. Federico,et al.  Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study , 2017, Oncology.

[13]  S. Vadaparampil,et al.  Racial disparities in BRCA testing and cancer risk management across a population‐based sample of young breast cancer survivors , 2017, Cancer.

[14]  L. Andrews,et al.  Hereditary Ovarian Cancer and Risk Reduction. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[15]  M. Pike,et al.  Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. , 2016, JAMA oncology.

[16]  P. Grant,et al.  Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy , 2016, International Journal of Gynecologic Cancer.

[17]  K. Jung,et al.  Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers , 2016, Journal of gynecologic oncology.

[18]  O. Gemer,et al.  Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers , 2015, International Journal of Gynecologic Cancer.

[19]  A. Toss,et al.  Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes , 2015, BioMed research international.

[20]  D. Alberts,et al.  Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Raine-Bennett,et al.  Risk management options elected by women after testing positive for a BRCA mutation. , 2014, Gynecologic oncology.

[22]  A. Tinker,et al.  Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers , 2013, Obstetrics and gynecology.

[23]  D. Oram,et al.  Outcome of risk‐reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status , 2011, BJOG : an international journal of obstetrics and gynaecology.

[24]  B. Rosen,et al.  The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. , 2011, Gynecologic oncology.

[25]  S. Mok,et al.  Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis , 2011, Cancer Prevention Research.

[26]  B. Crawford,et al.  Ovarian Pathology in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations, Emphasizing the Differential Diagnosis of Occult Primary and Metastatic Carcinoma , 2009, The American journal of surgical pathology.

[27]  J. Oosterwijk,et al.  Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? , 2009, International journal of cancer.

[28]  Ross S Berkowitz,et al.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mariza de Andrade,et al.  Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. , 2006, The Lancet. Oncology.

[30]  D. Bodurka,et al.  Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations , 2006, Obstetrics and gynecology.

[31]  N. Aaronson,et al.  Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F. Pansini,et al.  Seasonal onset of the menopause. , 2005, Maturitas.

[33]  Yoshio Miki,et al.  Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage , 2004, Cancer science.

[34]  B. Weber,et al.  Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. , 2004, Journal of Clinical Oncology.

[35]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[36]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[37]  H. Hollema,et al.  Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. , 2012, European journal of cancer.

[38]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[39]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.